CTNNA2 and cancer: Nonsynonymous mutations in four cancer-associated genes, CTNNA2 (11.1% vs. 5.8%; log10 p-value = −0.6), FLG (8.9% vs. 4.3%; log10 p-value = −0.6), GNAS (4.4% vs. 1.4%; log10 p-value = −0.5), and BCORL1 (17.0% vs. 11.6%; log10 p-value = −0.5), were more abundant in the case group.